mrsa
vrsa
recent
year
nh
pr
mo
subren
capsul
kidney
assay
iii
gal
gal
gal
galnac
tcid
median
tissu
cultur
infect
dose
tem
transmiss
electron
microscop
tgev
transmiss
gastroenter
viru
swine
tk
thymidin
kinas
defici
tunel
termin
deoxynucleotidyl
transferasemedi
nickend
label
stain
twi
tumor
weight
inhibit
vrsa
vancomycinresist
staphylococcu
aureu
polyoxometal
pm
discret
metaloxid
cluster
anion
high
solubl
water
photochem
electrochem
activ
properti
wide
varieti
structur
molecular
size
subnano
submicromet
variou
combin
metal
also
symmetri
highli
neg
charg
pope
hill
yamas
pope
et
al
yamas
proust
et
al
long
et
al
one
reason
structur
varieti
origin
conform
chang
due
condens
aggreg
structur
assembl
strongli
depend
environment
paramet
solut
ph
concentr
coexist
foreign
inorgan
andor
organ
substanc
therefor
pm
physiolog
condit
let
us
expect
induc
modif
varieti
biolog
system
adsorpt
receptor
penetr
substanc
cellular
membran
multipl
enzym
work
independ
cooper
interact
pm
multipl
biomolecul
target
singl
event
differ
process
simultan
biolog
system
provid
basi
develop
novel
inorgan
medicin
greatli
improv
understand
mechan
time
interact
speci
biolog
clinic
studi
well
vitro
vivo
antitumor
activ
polyoxomolybd
especi
mo
investig
along
line
sinc
find
vivo
antitumor
effect
solid
human
breast
lung
colon
cancer
xenograft
oat
respect
yamas
et
al
yamas
et
al
jasmin
et
al
jasmin
et
al
also
show
polyoxotungst
inhibit
rnadepend
dna
polymeras
retrovirus
let
us
expect
activ
human
immunodefici
viru
hiv
although
test
anim
model
lentivir
infect
infect
human
toxic
effect
clinic
trial
franc
usa
rozenbaum
et
al
moskovitz
et
al
spite
neg
vivo
antihiv
activ
assay
antivir
activ
pm
group
continu
mani
polyoxotungst
keggin
wellsdawson
relat
lacunari
multipli
condens
structur
particular
k
hill
et
al
inouy
et
al
fukuma
et
al
take
et
al
week
et
al
yamamoto
et
al
ikeda
et
al
shigeta
et
al
shigeta
et
al
barnard
et
al
rhule
et
al
witvrouw
et
al
also
observ
vitro
activ
nh
h
eu
moo
h
mo
naruk
et
al
interest
sinc
classifi
polyoxomolybd
although
attach
eu
atom
molecul
seem
biolog
signific
activ
inouy
et
al
howev
none
pm
yet
advantag
enough
surpass
clinic
approv
drug
deoxythymidin
azt
ribavirin
antivir
activ
cytotox
realiz
pmbase
inorgan
medicin
novel
drug
least
necessari
show
excel
activ
pm
biolog
target
imposs
replac
exist
approv
drug
alway
confront
histor
conserv
pessimist
background
inorgan
medicin
medicin
societi
yamas
shown
potent
activ
tri
vanadyl
iii
anion
v
iv
sbw
v
v
v
iv
sbw
wide
varieti
envelop
virus
infect
highrisk
individu
infant
born
prematur
cardiovascular
failur
pulmonari
dysplasia
hiv
select
index
si
valu
hiv
much
higher
azt
dextran
sulfat
mol
wt
shigeta
et
al
addit
antivir
polyoxotungst
exhibit
great
synergist
effect
antibiot
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
staphylococcu
aureu
vrsa
strain
yamas
et
al
fukuda
et
al
togeth
potenc
bacteria
streptococcu
pneumonia
helicobact
pylori
fukuda
yamas
synergi
effect
pm
let
us
investig
mechanist
detail
antibacteri
activ
relev
clarif
antivir
mechan
pm
mrsa
vrsa
streptococcu
pneumonia
gramposit
bacteria
helicobact
pylori
microaerophil
gramneg
bacterium
pose
seriou
problem
hospitalacquir
infect
surgic
intens
care
unit
global
infect
latter
associ
develop
gastriti
gastric
ulcer
duoden
ulcer
peptic
ulcer
gastric
cancer
approxim
half
world
popul
also
pm
enhanc
nerv
growth
factor
ngf
induc
neurit
growth
cell
express
axon
growth
associ
protein
oda
et
al
sinc
rat
neuron
cell
differenti
upon
ngf
stimul
use
vitro
model
character
neurotoxic
find
suggest
pm
may
one
candid
novel
drug
neurodegen
disord
alzheim
diseas
geng
et
al
review
recent
develop
biolog
antitumor
antivir
antimrsa
vrsa
bacteri
activ
pm
select
viewpoint
clinic
signific
figur
show
structur
anion
bioactiv
pm
discuss
yamas
et
al
ohashi
et
al
yamas
ishikawa
compound
antitumor
compound
latter
photoreduct
product
longterm
photolysi
ph
activ
former
yamas
et
al
domail
knoth
yamas
et
al
yamas
et
al
formal
trilacunari
keggin
structur
yield
symmetr
anion
wellsdawson
structur
p
w
anion
lyon
et
al
k
p
w
antivir
also
synergist
antibacteri
mrsa
vrsa
strain
coexist
antibodi
structur
shown
fig
symmetr
structur
consist
dimer
two
p
v
w
formal
trilacunari
keggin
structur
figur
fukuda
yamas
also
multipli
reduc
spheric
polyoxovanad
inhibit
strongli
nanomolar
level
vitro
enzymat
activ
specif
sialylsulfotransferas
respons
biosynthesi
cellsurfac
carbohydr
chain
trial
appli
pm
chemistri
medic
field
c
symmetr
vshape
heptamolybd
fig
c
symmetr
andersonstructur
polyoxomolybd
recogn
exhibit
antitumor
activ
solid
tumor
noncytotox
dose
vivo
yamas
et
al
oat
yamas
et
al
b
growth
suppress
superior
obtain
acnu
clinic
approv
drug
show
good
activ
breast
gastrointestin
intracrani
tumor
nh
pr
cl
browncolor
powder
photoreduct
product
metha
sarcoma
adenocarcinoma
five
compound
basic
administr
intraperiton
ip
nine
time
interv
day
subcutan
sc
ip
implant
tumor
cell
cell
metha
micegroup
femal
balbc
mice
metha
respect
day
tumor
weight
mg
tumor
weight
inhibit
twi
estim
measur
length
l
width
w
tumor
vernier
calip
mm
use
formula
lw
show
signific
inhibit
metha
sarcoma
high
valu
il
increas
lifespan
il
defin
c
c
c
mean
surviv
time
pmtreat
untreat
control
group
respect
especi
ip
administr
mgkg
provid
remark
prolong
il
ip
implant
easi
see
dose
schedul
il
valu
higher
acnu
administr
high
dose
acnu
significantli
differ
correspond
tumor
control
group
p
p
p
p
b
administr
peror
day
c
two
mice
per
group
die
day
inject
compound
two
mice
per
group
surviv
day
tumor
implant
free
tumor
lead
toxic
death
mice
indic
neg
chang
bodi
weight
also
effect
adenocarcinoma
cell
day
ad
yamas
ikawa
yamas
ishikawa
pr
cl
mgkg
hardli
effect
administr
mgkg
give
signific
inhibit
metha
sarcoma
growth
day
howev
consecut
administr
induc
neg
chang
bodi
weight
sinc
multipli
photoreduc
speci
origin
toxic
reflect
neg
chang
bodi
weight
seem
associ
high
condens
structur
produc
result
reduct
mo
small
size
mo
enabl
transport
across
membran
undergo
enzymemedi
metabol
bind
plasma
protein
tissu
satur
high
concentr
pathway
like
occur
result
nonlinear
relationship
dose
antitumor
activ
tabl
figur
show
effect
progress
growth
small
xenograft
human
breast
neoplasm
growth
human
breast
cancer
mm
implant
sc
athym
nude
mice
femal
balbc
micegroup
day
proce
detect
day
tumor
size
rang
mm
tumor
volum
v
determin
measur
two
princip
perpendicular
diamet
mm
v
length
width
first
administr
mgkg
ip
made
day
ten
administr
day
day
except
day
give
growth
inhibit
day
without
special
risk
mice
long
mice
appropri
steril
filtrat
mean
size
breast
tumor
day
tumor
size
mm
control
group
averag
tumor
weight
measur
kill
dissect
day
untreat
tumor
mice
ae
ae
g
respect
provid
appar
sign
toxic
fig
three
ip
administr
mgkg
day
result
death
one
mous
day
subsequ
seven
ip
administr
mgkg
day
day
give
toxic
death
anoth
mous
day
other
day
howev
therapi
exhibit
tumor
growth
inhibit
compar
control
group
day
thu
possibl
say
exhibit
cancerocid
potenc
similar
strongli
toxic
indic
optimum
administr
schedul
taken
consider
exemplifi
nude
mice
load
human
pancreat
cancer
human
gastric
cancer
growth
suppress
also
observ
nude
mice
bear
oat
human
lung
cancer
xenograft
human
colon
cancer
tumor
growth
suppress
pm
also
investig
use
subren
capsul
kidney
src
assay
small
piec
tumor
approxim
mm
implant
subren
capsul
icr
femal
mice
anesthesia
day
pm
ip
administr
day
day
thereaft
tumor
size
determin
day
result
src
assay
shown
tabl
na
imo
acnu
cisdiamminedichloroplatinum
ii
ccdp
also
evalu
comparison
fujita
et
al
yamas
et
al
b
yamas
yamas
antitumor
potenc
human
colon
cancer
compar
approv
drug
superior
anderson
structur
distribut
organ
tumorimpl
mice
investig
radioactiv
mo
analysi
liver
kidney
brain
plasma
tumor
h
ip
administr
mice
yamas
et
al
b
tumor
mice
prepar
implant
cell
day
mgkg
administr
ip
day
tumor
growth
detect
amount
mo
atom
uptaken
organ
h
ip
respect
comparison
amount
mo
atom
untreat
mice
indic
preferenti
distribut
kidney
tumor
hardli
brain
liver
fig
time
profil
amount
mo
atom
kidney
tumor
indic
maximum
within
h
ip
administr
excret
urin
h
fig
high
trap
mo
atom
kidney
let
us
presag
possibl
damag
kidney
howev
unpleas
effect
may
minim
maintain
rapid
urin
output
administr
high
solubl
gml
maximum
water
antitumor
activ
toxic
tabl
fig
compar
give
us
clue
mechan
antitumor
activ
mo
provid
gener
one
metabolit
biolog
system
well
photolysi
denot
eq
biolog
format
base
hypothesi
redox
potenti
electrondonor
site
within
tumor
cell
neg
enough
reduc
mo
high
toxic
seem
due
multielectron
redox
reaction
host
cell
addit
molecular
recognit
aris
symmetr
condens
anion
structur
fig
varieti
cation
mo
system
modifi
resid
time
mo
within
tumor
cell
lead
high
amount
mo
atom
well
solubl
stabil
physiolog
condit
agaros
gel
electrophoret
pattern
restrict
endonucleas
digest
plasmid
dna
treat
show
noncoval
bind
dna
tomita
et
al
differ
case
cddp
show
significantli
differ
correspond
tumor
control
group
p
p
p
p
coval
attach
atom
dna
guanin
base
dna
interstrand
crosslink
pinto
lippard
might
support
low
toxic
known
reduct
mo
biolog
possibl
format
complex
flavin
mononucleotid
fmn
format
constant
k
f
per
molar
ph
shown
fig
yamas
yamas
tomita
analysi
dc
polarogram
indic
differenti
puls
polarograph
peak
fmn
v
shift
posit
potenti
v
presenc
give
peak
potenti
v
impli
catalyt
reduct
complex
fmn
sinc
fmn
prosthet
group
flavoprotein
act
electron
carrier
electron
transfer
nadh
coenzym
q
coupl
atp
gener
site
stryer
seem
reason
assum
multielectron
reduct
mo
start
biolog
oneelectron
reduct
mo
fmn
complex
form
tumor
cell
mitochondria
result
suppress
tumor
growth
due
inhibit
atp
gener
preferenti
distribut
tumor
fig
support
propos
mechan
also
interact
mo
atp
investig
use
h
p
nmr
spectra
shown
mo
catalysi
atp
hydrolysi
adp
phosphat
ishikawa
yamas
impli
therapi
contribut
elong
surviv
rate
sinc
atp
hydrolysi
main
sourc
energi
biolog
process
crystal
isol
photolyt
ph
xray
crystallograph
character
chemic
formula
structur
insight
aqueou
solut
investig
use
mo
nmr
electron
absorpt
ir
electrospray
ioniz
mass
esim
spectrometri
anion
fig
mo
v
core
show
edgeshar
mo
v
octahedra
arrang
diamagnet
mo
v
pair
mo
v
mo
v
bond
distanc
cap
four
mo
vi
unit
remain
intact
ph
partial
detach
mo
vi
unit
occur
high
ph
level
accompani
increas
electron
transit
mo
v
pair
test
therapi
aggress
cancer
cell
poor
outcom
order
see
perspect
novel
inorgan
drug
base
pm
expectedli
show
cancerocid
potenc
human
pancreat
human
gastric
cancer
cell
effect
potenc
ogata
et
al
ogata
et
al
mitsui
et
al
vivo
cell
kill
cell
base
apoptosi
parallel
autophagi
ogata
et
al
cell
suspend
cultur
medium
gibco
carlbad
ca
usa
contain
ic
valu
cell
cell
respect
much
smaller
ic
valu
mgml
mm
mgml
mm
figur
show
surviv
rate
b
cell
treat
h
vivo
potenti
prolifer
cell
also
recogn
result
mice
exemplifi
fig
cell
transplant
back
nude
mice
day
intratumor
inject
dissolv
salin
perform
day
intermiss
day
control
mice
treat
salin
per
day
condit
inhibit
tumor
growth
day
implant
tumor
exampl
show
rate
dose
compar
control
respect
fig
tumor
observ
day
five
micegroup
administr
pictur
right
side
comparison
control
left
side
measur
micromet
calip
fig
loss
bodi
weight
mice
inject
experi
impli
cytotox
signific
far
present
therapi
least
employ
fig
littl
cytotox
therapi
support
also
hematolog
examin
blood
chemistri
assay
mice
treat
mg
bodyday
indic
damag
kidney
hepat
function
describ
thu
exhibit
antitumor
activ
inhibit
prolifer
human
pancreat
cancer
cell
dosedepend
manner
vivo
thin
section
tumor
day
singl
intratumor
inject
vivo
tumor
growth
inhibit
implant
mice
cell
transplant
back
balbc
nude
mice
day
intratumor
inject
dissolv
salin
perform
day
intermiss
day
control
mice
treat
salin
per
day
condit
chang
tumor
volum
bodi
weight
c
five
mice
per
group
depict
photograph
b
mice
day
tumor
implant
salin
salin
transplant
nude
mice
show
patholog
hyalin
hematoxylin
eosin
h
e
stain
termin
deoxynucleotidyl
transferasemedi
nickend
label
tunel
stain
figur
show
result
h
e
tunel
b
comparison
control
inject
nacl
salin
genotox
cell
growth
indic
format
apoptot
small
bodi
cell
due
dna
fragment
reveal
hoechst
dye
sigma
stain
suspens
contain
cell
treat
ic
h
ogata
et
al
ogata
et
al
mitsui
et
al
morpholog
analysi
hoechst
stain
indic
sharp
dna
ladder
pm
treatment
agaros
gel
electrophoresi
cell
dna
extract
allow
us
confirm
induct
apoptosi
transmiss
electron
microscop
tem
employ
analysi
ultrastructur
alter
cell
treat
ic
h
figur
show
tem
imag
cell
treat
without
ogata
et
al
averag
dimens
control
cell
rang
diamet
nucleu
rang
untreat
cell
control
number
roundshap
mitochondria
make
predomin
cytoplasm
featur
observ
along
extern
microvilli
fig
b
comparison
control
morpholog
alter
cell
treat
distinguish
occurr
chromatinchromosom
condens
damag
mitochondria
clark
former
nucleu
lead
apoptot
cell
death
fig
latter
cytoplasm
indic
format
smaller
round
organel
result
damag
throughout
swell
mitochondria
fig
cell
contain
number
autophagosom
autolysosom
cytoplasm
fig
characterist
featur
autophagi
ogata
et
al
signific
decreas
number
microvilli
surfac
treat
cell
suggest
littl
alter
membran
permeabl
exposur
cell
visual
autophagi
green
fluoresc
protein
gfp
tag
light
express
cell
autophag
process
concentr
autophagosom
therebi
punctat
fluoresc
emit
good
indic
autophagi
takeuchi
et
al
result
shown
fig
ogata
et
al
diffus
cytoplasm
local
observ
control
ic
h
treat
cell
transfect
express
plasmid
show
punctat
fluoresc
fig
express
ii
protein
cell
indic
autophagi
contrast
control
show
express
western
blot
pictur
fig
similar
result
also
obtain
cell
ogata
et
al
sinc
truncat
form
necessari
bind
seclus
membran
primari
stage
autophagi
takeuchi
et
al
result
reveal
pm
induc
activ
apoptosi
also
autophagi
cell
death
pathway
determin
factor
magnitud
apoptosi
autophagi
cell
death
remain
still
unclear
although
activ
regulatori
factor
could
identifi
use
assay
kit
lamparskaprzybysz
et
al
golstein
kroemer
h
last
intratumor
inject
mg
salin
per
day
procedur
employ
tumor
growth
inhibit
test
transplant
mice
fig
mice
anesthet
blood
sampl
taken
whole
blood
sampl
use
hematolog
test
blood
sera
assess
blood
urea
nitrogen
bun
creatinin
total
bilirubin
total
protein
aspart
aminotransferas
ast
alanin
aminotransferas
alt
alkalin
phosphatas
alp
tabl
show
result
control
mice
ml
salineday
condit
use
anim
treat
neg
control
mice
receiv
neither
tumor
transplant
intratumor
inject
ad
result
hematolog
examin
blood
chemistri
show
signific
differ
neg
control
neither
tumor
transplant
inject
group
indic
neither
impair
kidney
hepat
function
administr
model
ogata
et
al
may
candid
metabolit
vitro
vivo
inhibitori
solid
cancer
growth
mo
intratumor
inject
show
signific
efficaci
experiment
mice
inocul
model
indic
therapeut
use
altern
chemotherapi
togeth
fact
pancreat
cancer
aggress
form
cancer
one
poorest
outcom
cancer
develop
drugdeliveri
system
requir
realiz
novel
anticanc
drug
cours
vitro
antivir
assay
varieti
pm
especi
polyoxotungst
anion
shown
fig
exhibit
potent
inhibit
vitro
vivo
broad
spectrum
dna
virus
includ
herp
simplex
viru
hsv
type
hsv
type
thymidin
kinasedefici
tk
hsv
mutant
human
cytomegaloviru
hcmv
fukuma
et
al
dan
et
al
inhibit
viral
penetr
host
cell
second
round
infect
without
direct
interact
hsv
virion
dan
et
al
dan
et
al
cell
provid
approxim
enhanc
antihsv
potenc
compar
cell
treat
infect
dan
et
al
togeth
fact
inhibit
interact
hsv
envelop
protein
gd
glycosyl
ectodomain
cellsurfac
membran
protein
hvem
dan
yamas
pretreat
cell
suggest
strong
bind
hvem
dose
respons
vivo
activ
mice
infect
ip
pfu
shown
tabl
differ
dose
ip
administr
mice
daili
day
start
immedi
viru
tabl
toxic
test
mice
serum
chemistri
tabl
signific
protect
achiev
dose
rang
mgkg
acyclovir
acv
approv
drug
viral
dnapolymeras
inhibit
acvtriphosph
form
cell
hsv
elion
et
al
test
parallel
show
weak
antihsv
activ
even
administr
dose
mgkgday
day
effect
dose
ed
valu
surviv
rate
day
infect
mg
kgday
mgkgday
acv
lethal
dose
ld
valu
acv
ip
administr
mgkgday
respect
mechan
vivo
antihsv
activ
attribut
interfer
viru
uptak
cell
andor
clearanc
hsv
also
partial
activ
macrophag
ikeda
et
al
latter
effect
recogn
measur
phagocyt
activ
periton
macrophag
increas
ip
administr
mark
vivo
efficaci
due
multipl
mechan
involv
direct
inhibitori
effect
viru
replic
inhibit
viru
adsorpt
well
hostmedi
antivir
respons
activ
macrophag
activ
also
observ
immunosuppress
mice
ikeda
et
al
cc
ec
median
cytotox
effect
concentr
respect
valu
seven
pm
includ
four
vwmix
pm
day
ae
day
ae
day
b
ae
b
day
ae
three
tiwmix
pm
rna
virus
list
tabl
respect
shigeta
et
al
tabl
cc
valu
pm
madindarbi
canin
kidney
mdck
vero
cell
determin
use
bromid
mtt
colorimetri
cell
cultur
presenc
pm
varieti
concentr
c
day
watanab
et
al
inouy
et
al
inouy
et
al
mori
shigeta
vwand
tiwmix
keggin
wellsdawson
pm
fig
ribavirin
inhibitor
viral
rna
synthesi
due
inhibit
inosin
monophosph
dehydrogenas
activ
cell
gilbert
knight
inhibitori
cdv
dfv
respect
indic
ec
valu
anion
structur
fig
former
anion
oneelectron
oxid
speci
latter
anion
consist
v
iv
triangl
sandwich
two
sbw
ligand
significantli
potent
inhibitor
pm
also
inhibitori
dfv
caus
dengu
fever
recent
migrat
tropic
zone
mild
zone
rsv
caus
bronchiti
andor
pneumonia
respiratori
infect
among
infant
ec
valu
respect
dfv
rsv
known
clinic
import
pathogen
differ
antivir
activ
pm
among
varieti
rna
virus
may
associ
depend
composit
target
amino
acid
sequenc
viral
envelop
glycoprotein
indic
differ
inhibit
dextran
sulfat
compound
varieti
molecular
weight
hosoya
et
al
inhibit
simian
immunodefici
virus
concentr
low
seem
potent
antihiv
compound
yamamoto
et
al
also
inhibit
format
giant
cell
syncytium
cocultur
hivinfect
cell
uninfect
cell
antihiv
activ
pm
could
base
inhibit
virustocel
bind
due
high
affin
viral
glycoprotein
involv
viru
adsorpt
cell
sinc
good
correl
inhibitori
effect
cytopath
syncytium
format
also
close
correl
inhibitori
effect
syncytium
format
interact
viral
envelop
glycoprotein
select
indic
si
ec
vwmix
keggin
pm
especi
cell
line
higher
azt
inhibitor
revers
transcriptas
mitsuya
et
al
dextran
sulfat
mol
wt
inhibitor
syncytium
form
celltocel
infect
mitsuya
et
al
baba
et
al
callahan
et
al
tabl
show
result
multinuclear
activ
galactosidas
indic
magi
assay
hela
cell
line
kimpton
emerman
indic
si
valu
respect
higher
azt
strongli
support
high
antivir
activ
fact
cocultiv
cell
b
cell
provid
perfect
inhibit
syncytium
format
multinuclear
giant
cell
format
assist
plausibl
bind
pm
contrast
bind
bicyclam
deriv
octahydrochlorid
dihydr
methylen
receptor
andor
donzella
et
al
let
us
predict
clinic
synergist
antihiv
activ
use
combin
pm
vivo
antihiv
activ
carri
use
recombin
vaccinia
virus
rvv
express
env
gene
express
hiviiib
gagpol
gene
wild
wr
strain
wr
control
rvv
balbc
mice
femal
five
micegroup
infect
pfu
day
mgkg
day
k
vo
biw
botar
et
al
ip
daili
administr
day
day
day
infect
ovari
mice
remov
homogen
viru
activ
evalu
activ
supernat
vivo
result
cytotox
antivir
activ
b
three
pm
shown
fig
matsui
k
yamas
kobayashi
k
saha
xin
q
takeshita
f
okuda
k
unpublish
result
paper
prepar
shown
fig
pm
dose
challeng
determin
along
result
vivo
cytotox
pm
provid
surviv
rate
day
ip
administr
less
mgkgday
suppress
viral
activ
vivo
almost
activ
administr
mgkg
daymous
especi
exhibit
potent
antivir
activ
p
p
respect
fig
sinc
hiv
antigenspecif
immun
respons
detect
mice
treat
pm
viru
infect
infer
pm
interact
hiv
antigen
lead
suppress
viral
replic
along
vitro
result
inhibit
base
proteas
inhibit
propos
wellsdawson
structur
pm
contain
one
peroxoniobium
oxoniobium
unit
substitut
one
tungsten
unit
parent
framework
k
p
w
nbo
k
p
w
nbo
nbsubstitut
parent
p
w
fig
provid
high
stabil
physiolog
ph
level
judd
et
al
compound
exhibit
ec
cc
peripher
blood
mononuclear
cell
show
noncompetit
inhibit
purifi
proteas
inhibit
constant
ae
ae
nm
nacl
respect
unfortun
estim
ec
valu
inferior
nm
peptidemimet
pi
contain
bistetrahydrofuranyl
urethan
tmc
clinic
develop
proteas
inhibitor
yoshimura
et
al
declerq
well
known
initi
step
influenza
viru
replic
start
uniqu
interact
viru
particl
cellular
membran
shigeta
blumenth
et
al
influenza
viru
acquir
infect
cleavag
hemagglutinin
ha
peptid
envelop
action
host
cell
proteas
condit
low
endosom
ph
cleav
ha
molecul
chang
stereoscop
conform
nterminu
cleav
site
come
contact
cellular
membran
fuse
viru
envelop
simultan
influx
proton
matrix
protein
ion
channel
occur
result
uncoat
inner
coat
ribonucleoprotein
sheath
liber
ribonucleoprotein
rnp
move
nucleu
influenza
virus
classifi
three
type
b
c
base
differ
rnp
antigen
influenza
viru
subdivid
subtyp
base
differ
antigen
compon
ha
neuraminidas
na
viru
current
nomenclatur
system
human
influenza
viru
take
geograph
locat
first
isol
strain
number
year
isol
antigen
descript
ha
na
exampl
shigeta
pm
inhibitori
viru
adsorpt
stage
name
administr
pm
h
viru
infect
show
littl
efficaci
interestingli
keggin
structur
tiwmix
pm
inhibit
adsorpt
influenza
viru
fluva
onto
cell
membran
h
infect
inhibit
fusion
fluva
envelop
cellular
membran
h
infect
shigeta
et
al
differ
mechan
antiinfluenza
activ
led
vitro
vivo
synergist
efficaci
combin
ribavirin
viral
rna
synthesi
inhibitor
zanamivir
na
inhibitor
synergist
therapeut
effect
mice
infect
fluva
use
ribavirin
examin
shown
fig
shigeta
et
al
shigeta
et
al
control
mice
inbr
femal
balbc
infect
lethal
dose
fluva
correspond
median
tissu
cultur
infect
dose
tcid
titer
mdck
cell
line
h
infect
mice
micegroup
treat
aerosol
ribavirin
either
singli
combin
everi
h
day
compound
solut
prepar
phosphatebuff
salin
pb
solut
ph
infect
mice
expos
compound
use
continu
aerosol
gener
h
rate
distribut
solutionh
chamber
infect
mous
place
chamber
separ
averag
diamet
aerosol
particl
set
experi
dose
compound
given
mice
express
term
concentr
compound
stock
solut
use
aerosol
exposur
compounduntr
mice
die
day
infect
similarli
ribavirintr
mice
die
day
respect
mice
treat
ribavirin
respect
surviv
day
infect
ec
valu
ribavirin
day
infect
could
evalu
mm
respect
ribavirin
combin
treat
infect
mice
mice
surviv
day
infect
mice
surviv
still
end
experi
day
infect
shown
fig
ribavirintr
mice
show
surviv
day
infect
respect
thu
surviv
rate
mice
treat
combin
ribavirin
ratio
significantli
high
compar
one
either
ribavirin
lung
infect
untreat
mice
mice
treat
either
ribavirin
becam
swollen
redden
due
congest
hand
lung
infect
mice
treat
combin
mm
ribavirin
remain
normal
grayish
white
congest
viral
titer
lung
infect
mice
treat
without
andor
ribavirin
measur
everi
h
infect
lung
measur
remov
three
mice
group
prepar
procedur
infect
administr
therapeut
effect
experi
chang
viral
titer
lung
shown
fig
result
group
uninfect
untreat
mice
ad
result
four
group
infect
mice
without
compound
comparison
shigeta
et
al
detect
viru
uninfect
mice
viral
titer
infect
mice
lung
increas
tcid
g
h
infect
decreas
tcid
g
h
respect
viral
titer
lung
infect
mice
treat
combin
ribavirin
consist
lower
infect
mice
treat
either
ribavirin
identifi
target
antifus
activ
fluva
strain
select
sever
passag
fluva
mdck
cell
presenc
effect
dose
mutat
confer
resist
indic
isoleucin
lysin
locat
interfac
edg
trimer
molecul
fig
synergist
therapeut
effect
mice
infect
fluva
use
ribavirin
control
mice
inbr
femal
balbc
infect
ten
lethal
dose
fluva
correspond
median
tissu
cultur
infect
dose
tcid
titer
mdck
cell
line
h
infect
mice
ten
micegroup
treat
aerosol
ribavirin
either
singli
combin
everi
h
day
compound
solut
prepar
phosphatebuff
salin
pb
solut
ph
infect
mice
expos
compound
use
continu
aerosol
gener
h
rate
distribut
solutionh
chamber
infect
mous
place
chamber
separ
compound
fill
circl
treat
mm
ribavirin
substitut
threonin
asparagin
respect
strongli
impli
bind
interfac
edg
ha
trimer
inhibit
open
trimer
lead
inhibit
fusion
viral
envelop
cellular
membran
hydrophob
amino
acid
edg
cleavag
site
shigeta
shigeta
et
al
fusion
inhibit
uniqu
synergist
antiinfluenza
viru
activ
ribavirin
zanamivir
promis
novel
therapeut
drug
influenza
viru
infect
exemplifi
fig
congen
tiwmix
pm
eg
vwmix
pm
broad
antivir
activ
envelop
rna
virus
tabl
may
develop
broadspectrum
drug
acut
respiratori
infect
ari
caus
orthomyxovirus
influenza
virus
b
c
paramyxovirus
human
parainfluenza
virus
measl
viru
rsv
sinc
antivir
pm
inhibit
adsorpt
envelop
rna
virus
toward
host
cell
pm
expect
also
inhibit
sever
acut
respiratori
syndrom
coronaviru
sarsv
shigeta
yamas
sar
sever
highli
contagi
first
emerg
china
spread
within
month
origin
world
vitro
antivir
activ
tiwand
vwmix
pm
assay
sarsv
togeth
coronavirus
transmiss
gastroenter
viru
swine
tgev
felin
infecti
periton
viru
fipv
yamas
shigeta
et
al
shown
tabl
pm
exhibit
antitgev
activ
vwmix
pm
display
antisarsv
activ
show
appar
relationship
structur
antifipv
activ
overal
tri
vanadyl
anion
similar
deriv
anion
exhibit
efficaci
coronavirus
data
shown
structur
signific
tri
vanadyl
ring
moieti
point
observ
vitro
antivir
activ
coronavirus
first
step
infect
host
cell
influenza
viru
bind
adsorpt
influenza
viru
ha
sialic
acid
residu
carbohydr
side
chain
cellular
protein
project
plasma
membran
viru
exploit
receptor
second
step
conform
chang
ha
membran
fusogen
acid
ph
ph
c
optim
fusogen
activ
induc
fusion
viral
envelop
membran
membran
endosom
expel
viral
rna
cytoplasm
begin
replic
shigeta
blumenth
et
al
togeth
specif
bind
hvem
tnf
receptor
superfamili
suggest
investig
antihsv
activ
dan
yamas
therefor
antivir
mechan
pm
inhibit
adsorpt
envelop
rna
dna
virus
toward
host
cell
like
involv
function
quench
sialic
acid
residu
carbohydr
side
chain
cellular
protein
consid
bind
multipl
ha
ligand
influenza
viru
sialic
acid
surfac
receptor
erythrocyt
cell
viral
infect
occur
extrem
strong
affin
per
molar
associ
constant
singl
sialic
acidha
interact
per
molar
et
al
sialylsulfotransferas
respons
biosynthesi
fig
yamas
et
al
inhibit
vitro
enzymat
activ
specif
sialylsulfotransferas
gal
glcnac
gal
heparan
sulfat
subnano
nanomolar
concentr
noncompetit
inhibitori
mode
donor
acceptor
substrat
seko
et
al
exampl
inhibit
activ
inhibit
constant
k
nm
nm
core
acceptor
donor
respect
much
lower
k
nm
previous
report
lowest
inhibitor
glycosid
analogu
schmidt
inhibit
mode
shown
fig
plot
reciproc
veloc
versu
reciproc
substrat
concentr
without
steadyst
kinet
result
indic
noncompetit
inhibit
suggest
interact
varieti
bind
site
inhibitori
concentr
ic
valu
varieti
pm
two
sialylsulfotransferas
list
tabl
seko
et
al
ic
valu
extrem
small
nm
respect
valu
order
magnitud
smaller
nm
respect
nm
respect
nm
note
inhibit
pm
vitro
enzymat
activ
sialylsulfotransferas
least
stronger
known
inhibitor
schmidt
rath
et
al
result
inhibitori
effect
mutat
enzym
impli
inhibit
pm
adsorpt
envelop
rna
virus
toward
host
cell
due
strong
interact
pm
arg
residu
ctermin
region
also
basic
amino
acid
residu
seko
et
al
thu
type
pm
abil
inhibit
specif
sialylsulfotransferas
indic
pm
directli
inhibit
activ
enzym
involv
carbohydr
metabol
lead
inhibit
bind
ha
ligand
influenza
viru
sialic
acid
surfac
receptor
shown
tabl
activ
sialylsulfotransferas
enzym
correspond
miss
antivir
activ
polyoxomolybd
polyoxotungst
show
synergist
effect
antibiot
methicillinresist
staphylococcu
aureu
mrsa
gramposit
bacterium
first
isol
introduct
methicillin
clinic
use
aureu
strain
jevon
induc
clinic
seriou
problem
due
strong
resist
mani
antibiot
inhibit
methicillin
aureu
strain
base
bind
antibiot
penicillinbind
protein
pbpa
peptidoglycansynthet
enzym
membran
surfac
differ
methicillinsuscept
staphylococcu
aureu
mssa
mrsa
possess
sometim
call
meca
addit
pbp
membran
surfac
code
meca
gene
exhibit
low
affin
concern
exist
surfac
mrsa
strain
classifi
two
constitut
exist
irrespect
induc
induc
surfac
presenc
ubukata
et
al
matsuhashi
et
al
vancomycin
glycopeptid
becom
antibiot
last
resort
hardtotreat
infect
mrsa
infect
howev
event
bacteria
develop
resist
vancomycin
case
chang
amid
ester
bacteri
glycopeptid
cell
wall
precursor
sinc
vancomycinresist
aureu
vrsa
strain
first
isol
hanaki
et
al
b
vrsa
strain
emerg
produc
structur
unusu
complic
cell
wall
precursor
interact
vancomycin
boneca
chiosi
thu
novel
chemotherapeut
mrsa
vrsa
strain
strongli
requir
effect
pm
mrsa
strain
constitut
induc
investig
yamas
et
al
b
c
shown
tabl
minimum
inhibitori
concentr
mic
unit
fraction
inhibitori
concentr
fic
index
pm
measur
agar
dilut
checkerboard
method
evalu
effect
combin
oxacillin
halland
et
al
shown
tabl
polyoxotungst
test
studi
exhibit
synergist
effect
oxacillin
fic
index
less
defin
synergist
effect
particular
synergist
potenti
kegginstructur
polyoxotungst
lacunari
tabl
yamas
et
al
b
c
b
c
fukuda
et
al
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
membran
protein
separ
mrsa
reveal
synerg
polyoxotungst
due
inhibit
express
membran
surfac
pm
yamas
et
al
b
c
fukuda
et
al
three
pm
test
five
strain
two
constitut
mrsa
induc
mrsa
two
constitut
vrsa
strain
observ
enhanc
antibacteri
activ
antibiot
oxacillin
help
three
kind
pm
simo
summar
tabl
mic
valu
pm
determin
microdilut
method
also
ad
synerg
pm
oxacillin
antibacteri
activ
investig
oxacillinincorpor
disk
method
use
mh
agar
medium
pm
includ
test
concentr
observ
growthinhibitori
zone
around
oxacillin
disk
indic
suscept
test
strain
figur
show
typic
imag
growthinhibitori
zone
around
disk
strain
treat
appear
growthinhibitori
zone
indic
homoresist
strain
fig
observ
growthinhibitori
zone
coloni
insid
heteroresist
strain
fig
appear
growthinhibitori
zone
without
coloni
indic
oxacillinsuscept
strain
fig
test
strain
homoresist
absenc
pm
heteroresist
concentr
less
mic
valu
show
growthinhibitori
zone
yamas
et
al
fukuda
et
al
correct
strain
except
indic
transform
mrsa
resist
suscept
tabl
also
caus
chang
homoto
heteroresist
decreas
resist
phenotyp
chang
interestingli
simo
enabl
enhanc
antibacteri
activ
strain
sinc
growthinhibitori
zone
without
coloni
observ
concentr
less
mic
strong
contrast
case
kegginstructur
na
pmo
enhanc
antibacteri
activ
mrsa
tabl
differ
synerg
na
pmo
associ
structur
stabil
anion
physiolog
ph
level
verifi
cyclic
voltammetr
measur
shown
notat
homo
hetero
repres
homoresist
heteroresist
suscept
oxacillin
respect
notat
nc
indic
result
coloni
seen
agar
medium
concentr
pm
exceed
mic
inhibit
express
pm
result
miss
meca
gene
mrsa
strain
cultur
h
c
mh
broth
contain
pm
mic
thereaft
aliquot
broth
appli
onto
mh
agar
medium
absenc
pm
accord
standard
oxacillindisk
method
incub
h
c
howev
observ
growthinhibitori
zone
around
oxacillin
disk
mh
agar
medium
result
exclud
possibl
miss
meca
gene
pmstreat
mrsa
strain
sinc
pmtreat
strain
would
exhibit
oxacillin
suscept
meca
gene
miss
pm
next
step
possibl
inhibit
transcript
meca
gene
mrna
pm
without
oxacillin
investig
use
revers
transcript
polymeras
chain
reaction
rtpcr
analysi
mrsa
vrsa
strain
cultur
initi
stage
logarithm
growth
phase
od
presenc
pm
simo
alon
less
mic
coexist
pm
oxacillin
mic
bp
induc
mrna
togeth
bp
control
pcr
primer
mecapbp
gene
design
fragment
gene
amplifi
procedur
cycl
amplif
consist
denatur
c
primer
anneal
c
primer
extens
c
final
extens
ryffel
et
al
zhao
et
al
inhibit
transcript
meca
pbpa
mrna
rrna
quantit
evalu
band
intens
analyz
imageanalysi
softwar
shown
fig
simo
show
decreas
band
intens
mecainduc
mrna
concentr
less
mic
mic
display
inhibit
although
depress
band
intens
alon
concentr
less
mic
extent
decreas
increas
increas
concentr
comparison
rrna
indic
transcript
process
meca
mrna
inhibit
pm
also
rtpcr
result
show
pm
depress
also
express
pbpaand
mrna
extent
depress
depend
pm
pbp
gene
exemplifi
fact
inhibit
express
mrna
observ
pm
mic
concentr
inhibit
mrna
pm
demonstr
nice
morpholog
chang
swell
aggreg
strain
cell
cultiv
presenc
pm
observ
microscop
fukuda
et
al
notabl
inhibit
transcript
meca
pbp
gene
mrna
pm
enhanc
treatment
min
cell
mrsa
vrsa
simo
induc
blue
color
cell
strong
contrast
case
color
dead
cell
treat
ethanol
day
figur
show
blue
color
live
cell
protoplast
bluestain
cell
obtain
treatment
lysostaphin
mutanolysin
cell
wall
lysi
enzym
hyperton
solut
h
remain
still
blue
fact
biolog
reduct
simo
occur
mrsa
cell
also
vrsa
cell
much
thicker
cell
wall
indic
pm
penetr
cell
wall
uptaken
electron
transfer
system
cellular
membran
probabl
respir
system
involv
nadhubiquinonecytochromec
support
domin
distribut
w
atom
peripheri
element
spectrum
analysi
fukuda
et
al
redox
potenti
nadh
ubiquinon
cytochromec
v
vs
agagcl
respect
neg
enough
reduc
simo
sinc
cyclic
voltammogram
simo
ph
show
first
half
potenti
e
revers
oneelectron
reduct
v
v
vs
agagcl
respect
biolog
reduct
simo
note
also
photosystem
ii
photosynthesi
electron
transfer
photoreduc
pheophytin
primari
plastoquinon
acceptor
occur
simo
giaquinta
dilley
zilinska
govindje
thu
simo
biolog
easili
reduc
blue
color
show
broad
absorpt
band
around
nm
assign
interval
charg
transfer
v
om
vi
vi
om
v
w
mo
fukuda
et
al
figur
show
tem
imag
cell
treat
without
element
spectra
local
point
cell
observ
wti
atom
ratio
close
one
peripheri
cell
treat
strongli
impli
pm
enter
cell
local
cell
peripheri
keep
structur
anion
intact
strong
contrast
case
untreat
cell
indic
signific
intens
peak
due
w
ti
atom
anion
structur
pm
kept
intact
insid
cell
also
point
cholewa
et
al
cyclic
voltammogram
ph
show
first
half
potenti
e
pseudorevers
oneelectron
reduct
v
vs
agagcl
indic
biolog
redox
inact
cyclic
voltammogram
pmo
show
structur
decomposit
physiolog
ph
level
wherea
ph
provid
revers
twoelectron
reduct
v
vs
agagcl
decomposit
pmo
ph
ration
lack
synergist
activ
bacteri
atp
within
cytoplasm
membran
produc
cell
growth
electron
transfer
nadh
dissolv
oxygen
cytochromec
trigger
proton
gradient
insid
outsid
cell
therefor
fact
simo
two
order
magnitud
lower
mic
tabl
associ
block
electron
transfer
system
respir
lead
inhibit
atp
product
name
biolog
redoxact
simo
uptaken
cytoplasm
membran
inhibit
electron
transfer
system
mrsa
vrsa
lead
lower
mic
valu
cell
wall
mrsa
construct
meshlik
structur
peptidoglycan
polym
chain
compris
altern
sugar
unit
nacetylglucosamin
nacetylmuram
acid
lala
residu
tetrapeptid
laladglullysdala
peptidoglycan
bound
nacetylmuram
acid
termin
dala
residu
tetrapeptid
link
lli
residu
tetrapeptid
neighbor
polym
chain
pentaglycin
peptid
pm
nm
size
small
enough
pass
void
peptidoglycan
layer
reach
cytoplasm
membran
thu
reason
say
inhibit
transcript
meca
pbp
gene
mrna
exert
pm
uptaken
cytoplasm
membran
amount
strongli
associ
synergist
activ
enhanc
pminduc
inhibit
transcript
meca
pbp
gene
mrna
fig
give
us
clue
mechan
synergist
activ
pm
amount
w
atom
uptaken
cell
presenc
pm
andor
oxacillin
measur
induct
coupl
plasma
atom
emiss
spectroscopi
icp
analysi
mrsa
vrsa
cell
treat
mic
simo
without
mic
oxacillin
inoculum
cfu
colonyform
unit
ml
bacteria
mic
addit
mhb
medium
cultur
c
stage
logarithm
growth
phase
od
harvest
centrifug
wash
three
time
ultra
pure
water
freezedri
weight
dri
sampl
dissolv
nitric
acid
boil
filtrat
result
filtrat
use
icp
analysi
mrsa
vrsa
provid
highest
amount
w
mo
atom
cultur
pm
fig
tem
imag
cell
treat
without
element
spectra
local
point
cell
ad
pmtreat
b
untreat
one
inoculum
cfu
colonyform
unitml
inocul
mh
broth
contain
mm
h
c
cell
harvest
centrifug
g
min
c
wash
twice
pb
fix
glutaraldehyd
pb
follow
dehydr
grade
seri
ethanol
embed
resin
section
convent
method
spectrum
observ
jeol
f
examin
distribut
w
ti
atom
cell
help
energi
dispers
xray
analysi
jeol
oxacillin
compar
case
pm
alon
highlight
result
obtain
shown
fig
cultiv
bacteria
cell
coexist
oxacillin
mic
enhanc
uptak
w
atom
mrsa
vrsa
b
cell
p
n
hino
k
inou
oda
nakamura
yamas
unpublish
result
paper
prepar
interestingli
cfuml
cell
mic
oxacillin
alon
first
cultur
c
mhb
initi
stage
logarithm
growth
phase
cultur
mic
pm
amount
uptaken
pm
extrem
small
compar
three
cultur
mode
mic
pm
alon
initi
stage
logarithm
growth
phase
first
mic
pm
logarithm
growth
phase
subsequ
mic
oxacillin
h
combin
mic
pm
mic
oxacillin
signific
differ
amount
uptaken
pm
mode
latter
two
figur
exemplifi
amount
w
atom
uptaken
cell
varieti
cultiv
mode
cell
hino
k
inou
oda
nakamura
yamas
unpublish
result
paper
prepar
shown
fig
amount
uptaken
w
atom
mode
first
mic
pm
logarithm
growth
phase
subsequ
mic
oxacillin
h
higher
mic
pm
alon
initi
stage
logarithm
growth
phase
impli
increas
amount
pm
uptaken
cell
oxacillin
strongli
associ
enhanc
pm
inhibit
transcript
meca
pbp
gene
mrna
oxacillin
fig
provid
mechanist
key
enhanc
pm
uptak
membran
antibiot
captur
pbp
protein
membran
surfac
transient
diminish
within
h
initi
stage
mic
p
n
compounduntr
cell
control
show
observ
amount
w
atom
cell
logarithm
growth
od
bacteria
one
remark
atpbind
cassett
abc
transport
famili
membran
transport
system
encod
transcript
abca
gene
contribut
import
export
wide
rang
substanc
protein
peptid
polysaccharid
vitamin
drug
use
atp
higgin
maupinfurlow
et
al
grunden
shanmugam
well
known
methicillin
antibiot
oxacillin
cefoxitin
stimul
transcript
abca
gene
abca
express
induc
increas
concentr
methicillin
induct
obtain
h
exposur
methicillin
sinc
transcript
abca
reach
maximum
later
exponenti
growth
phase
schraderfisch
therefor
differ
pmsuptak
pattern
among
differ
cultur
mode
fig
seem
associ
maximum
observ
transcript
abca
induc
oxacillin
oxacillininduc
increas
pm
uptaken
cytoplasm
membran
make
base
synergist
activ
pm
sinc
pm
within
cytoplasm
membran
indirectli
inhibit
meca
pbp
transcript
lead
inhibit
pbpa
express
membran
surfac
fig
icp
analysi
mrsa
vrsa
cell
treat
mic
pm
also
reveal
preferenti
uptak
na
ratio
ten
compar
case
absenc
pm
cell
counter
cation
pm
anion
although
mg
k
ca
cation
detect
hino
k
togeth
locat
pm
within
cytoplasm
membran
thu
electr
field
aris
electrochem
pmsna
doubl
layer
cell
insid
enhanc
contribut
inhibit
meca
pbp
transcript
result
depress
transcript
process
reflect
synergi
pm
mrsa
vrsa
strain
kegginand
wellsdawsonstructur
pm
employ
nh
mo
littl
synergist
tabl
exhibit
signific
uptak
cell
irrespect
oxacillin
support
synergist
mechan
pm
howev
mechan
synergi
necessarili
exclud
sinc
rtpcr
result
doubl
kegginstructur
pm
k
h
geti
w
larger
ionic
size
suggest
inhibit
posttranscript
process
either
translat
mrna
posttransl
fold
translat
polypeptid
chain
vitro
activ
dna
rna
virus
show
potent
inhibit
vitro
vivo
broad
spectrum
dna
virus
includ
herp
simplex
viru
tkhsv
hcmv
vivo
antihsv
activ
attribut
interfer
viru
uptak
cell
andor
clearanc
hsv
also
partial
activ
macrophag
tiwand
vwmix
pm
broad
antivir
activ
envelop
rna
virus
hiv
fluva
sarsv
infect
highrisk
individu
caus
sever
manifest
often
result
fatal
signific
vivo
potenti
hiv
recogn
pm
inhibitori
viru
adsorpt
stage
eg
due
bind
pm
inhibit
adsorpt
influenza
viru
fluva
onto
cell
membran
h
infect
inhibit
fusion
fluva
envelop
cellular
membran
h
infect
differ
mechan
antiinfluenza
activ
led
vitro
vivo
synergist
efficaci
combin
ribavirin
viral
rna
synthesi
inhibitor
zanamivir
na
inhibitor
antifus
activ
investig
use
fluva
strain
attribut
bind
interfac
edg
ha
trimer
inhibit
open
trimer
fluva
found
pm
inhibit
specif
sialylsulfotransferas
vitro
enzymat
activ
least
stronger
known
inhibitor
impli
pm
directli
inhibit
activ
enzym
involv
carbohydr
metabol
lead
inhibit
bind
ha
ligand
influenza
viru
sialic
acid
surfac
receptor
synergist
effect
pm
antibiot
basi
develop
novel
chemotherapi
mrsavrsainfect
diseas
kegginstructur
polyoxotungst
lacunari
speci
xw
xw
exhibit
synergist
effect
oxacillin
fic
indic
mechanist
detail
synergist
activ
pm
five
strain
two
constitut
mrsa
induc
mrsa
two
constitut
vrsa
strain
investig
use
k
p
w
k
simo
simo
abc
transport
particip
transport
pm
cytoplasm
membran
accompani
preferenti
flow
na
counter
cation
activ
captur
membran
surfac
therebi
uptaken
pm
within
membran
make
electrochem
doubl
layer
na
cation
insid
cytoplasm
transcript
meca
pbp
gene
mrna
depress
within
pmna
electr
doubl
layer
lead
depress
format
pbp
enzym
membran
surfac
togeth
pbp
bind
membran
surfac
enhanc
pminduc
suppress
pbp
express
provid
base
synergist
activ
combin
pm
vivo
experi
requir
develop
novel
chemotherapi
mrsavrsainfect
diseas
certif
mechan
